A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs CNM Au8 (Primary)
- Indications Demyelinating disorders; Multiple sclerosis; Optic neuritis
- Focus Therapeutic Use
- Acronyms VISIONARY-MS
- 14 Oct 2019 According to the Clene Nanomedicine media release, the National Multiple Sclerosis Society (NMSS) has awarded the company a research grant totaling more than $339,000. The Fast Forward grant will support pharmacodynamic studies to determine the effects of CNM-Au8 on various biological markers from patients in the VISIONARY-MS remyelination Phase 2 study.
- 16 Jan 2019 Planned End Date changed from 31 Dec 2019 to 30 Mar 2020.
- 16 Jan 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Dec 2019.